These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 7767251)

  • 1. CHLVPP therapy for Hodgkin's disease identification of prognostic factors.
    Vose JM
    Leuk Lymphoma; 1995; 15 Suppl 1():13-4. PubMed ID: 7767251
    [No Abstract]   [Full Text] [Related]  

  • 2. ChlVPP: reducing toxicity in the treatment of Hodgkin's disease.
    Mansi JL
    Eur J Cancer; 1992; 28A(8-9):1411-3. PubMed ID: 1515260
    [No Abstract]   [Full Text] [Related]  

  • 3. ChlVPP chemotherapy in advanced Hodgkin's disease.
    McKendrick JJ; Mead GM; Sweetenham J; Jones DH; Williams CJ; Ryall R; Whitehouse JM
    Eur J Cancer Clin Oncol; 1989 Mar; 25(3):557-61. PubMed ID: 2703008
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Treatment outcome of advanced Hodgkin's disease based on using an alternating program ChLVPP (chlorambucil, vinblastine, procarbazine, prednisone) and ABV (doxorubicin, bleomycin, vinblastine)].
    Komarnicki M; Balcerzak A; Górski P; Pawlak L; Hansz J
    Acta Haematol Pol; 1994; 25(4):363-8. PubMed ID: 7531381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ChlVPP therapy for Hodgkin's disease: experience of 960 patients. The International ChlVPP Treatment Group.
    Ann Oncol; 1995 Feb; 6(2):167-72. PubMed ID: 7786824
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ChlVPP alternating with PABlOE is superior to PABlOE alone in the initial treatment of advanced Hodgkin's disease: results of a British National Lymphoma Investigation/Central Lymphoma Group randomized controlled trial.
    Hancock BW; Gregory WM; Cullen MH; Hudson GV; Burton A; Selby P; Maclennan KA; Jack A; Bessell EM; Smith P; Linch DC; ;
    Br J Cancer; 2001 May; 84(10):1293-300. PubMed ID: 11355937
    [TBL] [Abstract][Full Text] [Related]  

  • 7. ChlVPP--an effective and well-tolerated alternative to MOPP therapy for Hodgkin's disease.
    Vose J; Armitage J; Weisenburger D; Moravec D; Hutchins M; Howe D; Sorensen S; Dowling M; Okerbloom J; Pevnick W
    Am J Clin Oncol; 1988 Aug; 11(4):423-6. PubMed ID: 3407620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hodgkin's disease in the elderly: improved treatment outcome with a doxorubicin-containing regimen.
    Weekes CD; Vose JM; Lynch JC; Weisenburger DD; Bierman PJ; Greiner T; Bociek G; Enke C; Bast M; Chan WC; Armitage JO;
    J Clin Oncol; 2002 Feb; 20(4):1087-93. PubMed ID: 11844834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CHLVPP chemotherapy with involved-field irradiation for Hodgkin's disease: favorable results with acceptable toxicity.
    Vose JM; Bierman PJ; Anderson JR; Weisenburger D; Moravec DF; Sorensen S; Hutchins M; Dowling MD; Howe D; Okerbloom J
    J Clin Oncol; 1991 Aug; 9(8):1421-5. PubMed ID: 2072145
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ChlVPP/PABlOE and radiotherapy in advanced Hodgkin's disease. The Central Lymphoma Group.
    Cullen MH; Stuart NS; Woodroffe C; Murphy A; Fletcher J; Blackledge GR; Child JA; Grieve RJ; Jones EL
    J Clin Oncol; 1994 Apr; 12(4):779-87. PubMed ID: 7512132
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of a randomized trial comparing MVPP chemotherapy with a hybrid regimen, ChlVPP/EVA, in the initial treatment of Hodgkin's disease.
    Radford JA; Crowther D; Rohatiner AZ; Ryder WD; Gupta RK; Oza A; Deakin DP; Arnott S; Wilkinson PM; James RD
    J Clin Oncol; 1995 Sep; 13(9):2379-85. PubMed ID: 7666097
    [TBL] [Abstract][Full Text] [Related]  

  • 12. ChlVPP/EVA hybrid versus the weekly VAPEC-B regimen for previously untreated Hodgkin's disease.
    Radford JA; Rohatiner AZ; Ryder WD; Deakin DP; Barbui T; Lucie NP; Rossi A; Dunlop DJ; Cowan RA; Wilkinson PM; Gupta RK; James RD; Shamash J; Chang J; Crowther D; Lister TA
    J Clin Oncol; 2002 Jul; 20(13):2988-94. PubMed ID: 12089229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAPE/PALE salvage chemotherapy for Hodgkin's disease patients relapsing within 1 year of ChlVPP chemotherapy.
    Fairey AF; Mead GM; Jones HW; Sweetenham JW; Whitehouse JM
    Ann Oncol; 1993 Dec; 4(10):857-60. PubMed ID: 8117605
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with MOPP or ChlVPP chemotherapy only for all stages of childhood Hodgkin's disease.
    Ekert H; Waters KD; Smith PJ; Toogood I; Mauger D
    J Clin Oncol; 1988 Dec; 6(12):1845-50. PubMed ID: 3058876
    [TBL] [Abstract][Full Text] [Related]  

  • 15. ChlVPP/ABV-VP16 hybrid regimen for advanced Hodgkin's disease: a study in 36 patients.
    Saletti P; Zucca E; Gueneau M; Peccatori F; Cavalli F; Martinelli G
    Leuk Lymphoma; 1999 Apr; 33(3-4):313-9. PubMed ID: 10221511
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ChlVPP/ABVVP, a first line 'hybrid' combination chemotherapy for advanced Hodgkin's lymphoma: a retrospective analysis.
    Martinelli G; Cocorocchio E; Peccatori F; Zucca E; Saletti PC; Calabrese L; Pastano R; Pruneri G; Mazzetta C; Ghielmini M; Cavalli F
    Br J Haematol; 2004 Jun; 125(5):584-9. PubMed ID: 15147373
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of Hodgkin's disease.
    Malpas JS
    J R Coll Physicians Lond; 1980 Jan; 14(1):26-33. PubMed ID: 6160241
    [No Abstract]   [Full Text] [Related]  

  • 18. Mechlorethamine, vinblastine, procarbazine and prednisolone (MVPP) for advanced Hodgkin's disease.
    Harding MJ; McNulty LJ; Paul J; Lee F; Brown A; Soukop M
    Eur J Cancer; 1991; 27(8):1002-6. PubMed ID: 1832882
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcome in children with Hodgkin's lymphoma: the United Kingdom Children's Cancer Study Group HD82 trial.
    Capra M; Hewitt M; Radford M; Hayward J; Weston CL; Machin D;
    Eur J Cancer; 2007 May; 43(7):1171-9. PubMed ID: 17379506
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hodgkin's disease.
    Saven A
    N Engl J Med; 1992 Aug; 327(7):499; author reply 499-500. PubMed ID: 1625747
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.